BrainsWay Ltd. (BWAY) has reported several key developments impacting its operations and financial outlook for the current quarter.

**Financial and Operational Highlights:**
*   BrainsWay reported record quarterly revenue of $12.6 million for the second quarter of 2025, an increase of 26% compared to the second quarter of 2024.
*   Net profit for the second quarter of 2025 increased by 233% year-over-year to $2.0 million.
*   Adjusted EBITDA for the second quarter of 2025 increased 16% to $1.5 million.
*   The company maintained a gross margin of 75% for the quarter.
*   BrainsWay shipped 88 Deep TMS™ systems in Q2 2025, marking a 35% year-over-year increase, and bringing the total installed base to 1,522 systems.
*   Approximately 70% of recent customer engagements are structured as multi-year lease agreements, representing $62 million in remaining performance obligations.
*   As of June 30, 2025, cash, cash equivalents, restricted cash, and short-term deposits totaled $78.3 million.
*   Based on strong performance, BrainsWay raised its full-year 2025 revenue guidance to between $50 million and $52 million (previously $49 million and $51 million). The company also raised its Adjusted EBITDA guidance for full-year 2025 to 12% to 13% (previously 11% to 12%).

**Clinical and Regulatory Developments:**
*   On June 11, 2025, BrainsWay announced positive results from a multicenter randomized trial evaluating an accelerated Deep TMS protocol for Major Depressive Disorder (MDD). The study demonstrated comparable efficacy to the standard protocol while significantly reducing treatment duration, with patients receiving five 10-minute sessions daily over six days plus eight continuation sessions, compared to traditional daily sessions over six weeks. Median remission for the accelerated group was achieved in 21 days, versus 28 days for standard treatment, with no serious adverse events reported.
*   Data from this accelerated protocol trial has been submitted to the U.S. FDA, with potential clearance anticipated by the fourth quarter of 2025.
*   The company is continuing progress with the Israel Ministry of Defense's Rehabilitation Department in qualifying patients with Post-Traumatic Stress Disorder (PTSD) for Deep TMS.
*   BrainsWay is working on data collection for PTSD and adolescent MDD, aiming to submit this data to the FDA later in 2025.

**Strategic Investments and Partnerships:**
*   On August 13, 2025, BrainsWay entered an equity financing transaction with Stella MSO, LLC, a management services organization that supports over 20 mental health clinics in the U.S. and Israel. BrainsWay invested $5 million in Stella MSO.
*   In August 2025 (August 21, 2025), BrainsWay made a strategic investment in Neurolief, a company developing the Proliv™Rx system for Major Depressive Disorder, which is awaiting FDA approval.
*   The company aims to secure five mental health network contracts by 2026.

**Other Events:**
*   BrainsWay served as a Gold Sponsor for the Clinical TMS Society's 2025 Annual Meeting, which took place from June 12-14, 2025, in San Diego, CA.
*   On July 30, 2025, BrainsWay announced its sponsorship of two free Continuing Medical Education (CME) courses for mental health professionals.